Date:	_2023-3-9
Your Name:	_ Hong Yu
Manuscript <sup>1</sup>	Title: Monitoring Early Response to Neoadjuvant Chemotherapy and Influences on
Neoadjuva	nt Chemotherapy response in Primary Osteosarcoma
Manuscript I	number (if known): QIMS-22-1095-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	<b>X</b> None	

5	Dayment or heneraria for	V None	
5	Payment or honoraria for lectures, presentations,	<b>X</b> None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<b>X</b> None	
	testimony		
7	Support for attending meetings and/or travel	<b>X</b> None	
	<b>G</b> ,		
8	Patents planned, issued or	V None	
0	pending	<b>X</b> None	
	P		
9	Participation on a Data	<b>X</b> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<b>X</b> None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	<b>X</b> None	
11	Stock of Stock options	<b>X</b> NOTIE	
12	Receipt of equipment,	<b>X</b> None	
	materials, drugs, medical		
	writing, gifts or other		
42	services		
13	Other financial or non- financial interests	<b>X</b> None	
	illianciai iliterests		
Plea	se summarize the above co	nflict of interest in the follo	owing box:
No	one.		

Date: 2023-3-9
Your Name:_ Lei Gao
Manuscript Title: Monitoring Early Response to Neoadjuvant Chemotherapy and Influences on
Neoadjuvant Chemotherapy response in Primary Osteosarcoma
Manuscript number (if known): QIMS-22-1095-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Dayment or heneraria for	V None	
5	Payment or honoraria for lectures, presentations,	<b>X</b> None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<b>X</b> None	
	testimony		
7	Support for attending meetings and/or travel	<b>X</b> None	
	<b>G</b> ,		
8	Patents planned, issued or	V None	
0	pending	<b>X</b> None	
	P		
9	Participation on a Data	<b>X</b> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<b>X</b> None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	<b>X</b> None	
11	Stock of Stock options	<b>X</b> NOTIE	
12	Receipt of equipment,	<b>X</b> None	
	materials, drugs, medical		
	writing, gifts or other		
42	services		
13	Other financial or non- financial interests	<b>X</b> None	
	illianciai iliterests		
Plea	se summarize the above co	nflict of interest in the follo	owing box:
No	one.		

Date: 2023-3-9	
Your Name: Ruiqing Shi	
Manuscript Title: Monitoring Early Response to Neoadjuvant Chemotherap	y and Influences on
Neoadjuvant Chemotherapy response in Primary Osteosarcoma	
Manuscript number (if known): QIMS-22-1095-R1	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Time frame: Since the initialXNone	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Dayment or hereraria for	V None	
5	Payment or honoraria for lectures, presentations,	<b>X</b> None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<b>X</b> None	
	testimony		
7	Support for attending meetings and/or travel	<b>X</b> None	
	<b>G</b> ,		
8	Patents planned, issued or	V None	
0	pending	<b>X</b> None	
	P		
9	Participation on a Data	<b>X</b> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<b>X</b> None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	<b>X</b> None	
11	Stock of Stock options	<b>X</b> NOTIE	
12	Receipt of equipment,	<b>X</b> None	
	materials, drugs, medical		
	writing, gifts or other		
42	services		
13	Other financial or non- financial interests	<b>X</b> None	
	illianciai iliterests		
Plea	se summarize the above co	nflict of interest in the follo	owing box:
No	one.		

Date: 2023-3-9
Your Name:_ Mengjuan Kong
Manuscript Title: Monitoring Early Response to Neoadjuvant Chemotherapy and Influences on
Neoadjuvant Chemotherapy response in Primary Osteosarcoma
Manuscript number (if known): QIMS-22-1095-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Time frame: Since the initialXNone	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Dayment or hereraria for	V None	
5	Payment or honoraria for lectures, presentations,	<b>X</b> None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<b>X</b> None	
	testimony		
7	Support for attending meetings and/or travel	<b>X</b> None	
	<b>G</b> ,		
8	Patents planned, issued or	V None	
0	pending	<b>X</b> None	
	P		
9	Participation on a Data	<b>X</b> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<b>X</b> None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	<b>X</b> None	
11	Stock of Stock options	<b>X</b> NOTIE	
12	Receipt of equipment,	<b>X</b> None	
	materials, drugs, medical		
	writing, gifts or other		
42	services		
13	Other financial or non- financial interests	<b>X</b> None	
	illianciai iliterests		
Plea	se summarize the above co	nflict of interest in the follo	owing box:
No	one.		

Date: 2023-3-9
Your Name:_ Lisha Duan
Manuscript Title: Monitoring Early Response to Neoadjuvant Chemotherapy and Influences on
Neoadjuvant Chemotherapy response in Primary Osteosarcoma
Manuscript number (if known): QIMS-22-1095-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Dayment or heneraria for	V Name		
Э	Payment or honoraria for lectures, presentations, speakers bureaus,	<b>X</b> None		
	manuscript writing or			
	educational events			
6	Payment for expert	<b>X</b> None		
	testimony			
7	Support for attending meetings and/or travel	<b>X</b> None		
	G ,			
8	Patents planned, issued or	<b>X</b> None		
	pending			
9	Participation on a Data	<b>X</b> None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role in other board, society,	<b>X</b> None		
	committee or advocacy group, paid or unpaid			
11	Stock or stock options	<b>X</b> None		
	Stock of Stock options	XNone		
12	Receipt of equipment,	<b>X</b> None		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-	<b>X</b> None		
financial interests	financiai interests			
Please summarize the above conflict of interest in the following box:				
N	None.			

Date: 2023-3-9
Your Name:_ Jianling Cui
Manuscript Title: Monitoring Early Response to Neoadjuvant Chemotherapy and Influences or
Neoadjuvant Chemotherapy response in Primary Osteosarcoma
Manuscript number (if known): QIMS-22-1095-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Dayment or heneraria for	V Name		
Э	Payment or honoraria for lectures, presentations, speakers bureaus,	<b>X</b> None		
	manuscript writing or			
	educational events			
6	Payment for expert	<b>X</b> None		
	testimony			
7	Support for attending meetings and/or travel	<b>X</b> None		
	G ,			
8	Patents planned, issued or	<b>X</b> None		
	pending			
9	Participation on a Data	<b>X</b> None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role in other board, society,	<b>X</b> None		
	committee or advocacy group, paid or unpaid			
11	Stock or stock options	<b>X</b> None		
	Stock of Stock options	XNone		
12	Receipt of equipment,	<b>X</b> None		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-	<b>X</b> None		
financial interests	financiai interests			
Please summarize the above conflict of interest in the following box:				
N	None.			